October/November #191 : Concerns: Early Treatment in Developing World - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

¡El SIDA Sí Da!

Cut to Fit

From the Editor

Rie y Llora

Feedback

Letters-October/November 2013

The POZ Q+A

Unidos Podemos

POZ Planet

Thank You, Sean Sasser

On the March

Get Lucky

Friend Request

Then There Were None

Why Should Gay and Bi Latino Men Get Tested?

Say What? Zombie Edition

Voices

Obamacare is Here

Care and Treatment

Reduced Dose of Sustiva Succeeds

New Ways to Beat Gonorrhea

Lower Bone Density Linked to Number of ARV Regimens

No Detectable HIV in Two Men After Stem Cell Transplants

WHO Revises Treatment Guidelines

Research Notes

Prevention: HIV Test May Help Improve Vaccines

Treatment: Normal Mortality Risk if Undetectable?

Cure: Cord Blood Transplant Aftermath

Concerns: Early Treatment in Developing World

POZ Heroes

A Test of Kindness

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

October / November 2013

Concerns: Early Treatment in Developing World

by Benjamin Ryan

While the World Health Organization recently recommended beginning HIV treatment once CD4s hit 500 or below, researchers from Johns Hopkins University have raised doubts of both the feasibility and the ethics of such a treatment expansion, considering the health care disparities between first and third world nations. Publishing in the journal Clinical Infectious Diseases, the scientists acknowledge that research clearly shows that early use of antiretrovirals (ARVs) benefits both HIV prevention efforts and people living with the virus. However, they argue that because the ARVs available at this time in resource-poor settings are often more outdated drugs, there are increased risks of side effects and toxicity weighing against the potential therapeutic benefits of early therapy. In addition, less effective therapies and inadequate or nonexistent laboratory monitoring may lead people to develop drug resistance, thus potentially limiting future treatment options.

Search: World Health Organization, WHO, Johns Hopkins University, treatment expansion

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    Drew949
    South Orange County
    California


    Reginaldb06
    Atlanta
    Georgia


    jimmy807
    San Antonio
    Texas


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.